EverSource Wealth Advisors’s Akero Therapeutics AKRO Stock Holding History

EverSource Wealth Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-60	Closed	-$2.85K	–	4275
2025 Q3	$2.85K	Sell	60 -27	-31%	-$1.31K	﹤0.01%	3397
2025 Q2	$4.64K	Buy	87 +17	+24%	+$772	﹤0.01%	3190
2025 Q1	$2.83K	Buy	70 +61	+678%	+$2.59K	﹤0.01%	2762
2024 Q4	$250	Buy	+9	New	+$273	﹤0.01%	3381

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EverSource Wealth Advisors's AKRO Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 60 shares — an estimated $2.85K sold.

EverSource Wealth Advisors first reported a position in AKRO in Q4 2024 and held it in 4 quarters. The position peaked at $4.64K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

EverSource Wealth Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 60 Akero Therapeutics shares in Q4 2025, an estimated $2.85K.
EverSource Wealth Advisors first reported a position in Akero Therapeutics in Q4 2024 and held it in 4 quarters.
EverSource Wealth Advisors's Akero Therapeutics position peaked at $4.64K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.